Raymond James Starts Fusion Pharmaceuticals (FUSN) at Outperform; Sees 200% Upside
Tweet Send to a Friend
(Updated - June 23, 2023 8:25 AM EDT)
Raymond James analyst Rahul Sarugaser initiates coverage on Fusion Pharmaceuticals (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Raymond James analyst Rahul Sarugaser initiates coverage on Fusion Pharmaceuticals (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
